Jinbo Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jinbo Huang has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Jiahao Li
Organ Transplant Center, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
13 shared publications - Meiting Qin
Organ Transplant Center, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
13 shared publications - Qiang Zhao
Organ Transplant Center, The First Affiliated Hospital Sun Yat‐sen University Guangzhou China
13 shared publications - Xiaoshun He
Organ Transplantation Center, The First Affiliated Hospital Sun Yat‐sen University Guangzhou China
13 shared publications - Zhiying Liu
Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China
13 shared publications - Haidong Tan
Second Department of Hepatopancreatobiliary Surgery, China-Japan Friendship Hospital, Beijing, China
12 shared publications
Latest Publications
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Figure 5 from HBV-Specific TCR–T Cell Therapy Combining mRNA Electroporation and Lentiviral Transduction: Treatment Regimen for Recurrent HBV-Related HCC after Liver Transplantation
A–F, Activity of HBV–TCR–T cells in peripheral blood at various time points. The black vertical dashed lines indicate the infusion time points for mRNA–HBV–TCR–T cells, and the red vertical dashed lines indicate the infusion time points of lenti-HBV–TCR–T cells.
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from HBV-Specific TCR–T Cell Therapy Combining mRNA Electroporation and Lentiviral Transduction: Treatment Regimen for Recurrent HBV-Related HCC after Liver Transplantation
A–F, Activity of HBV–TCR–T cells in peripheral blood at various time points. The black vertical dashed lines indicate the infusion time points for mRNA–HBV–TCR–T cells, and the red vertical dashed lines indicate the infusion time points of lenti-HBV–TCR–T cells.
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Figure 4 from HBV-Specific TCR–T Cell Therapy Combining mRNA Electroporation and Lentiviral Transduction: Treatment Regimen for Recurrent HBV-Related HCC after Liver Transplantation
A–F, Changes in inflammatory cytokine levels at different time points during the HBV–TCR–T cell treatment. MIG, monokine induced by gamma interferon.
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from HBV-Specific TCR–T Cell Therapy Combining mRNA Electroporation and Lentiviral Transduction: Treatment Regimen for Recurrent HBV-Related HCC after Liver Transplantation
A–F, Changes in inflammatory cytokine levels at different time points during the HBV–TCR–T cell treatment. MIG, monokine induced by gamma interferon.
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from HBV-Specific TCR–T Cell Therapy Combining mRNA Electroporation and Lentiviral Transduction: Treatment Regimen for Recurrent HBV-Related HCC after Liver Transplantation
Schematic representation of the production workflow of HBV–TCR–T cells. QC, quality control.
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from HBV-Specific TCR–T Cell Therapy Combining mRNA Electroporation and Lentiviral Transduction: Treatment Regimen for Recurrent HBV-Related HCC after Liver Transplantation
Schematic representation of the production workflow of HBV–TCR–T cells. QC, quality control.
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from HBV-Specific TCR–T Cell Therapy Combining mRNA Electroporation and Lentiviral Transduction: Treatment Regimen for Recurrent HBV-Related HCC after Liver Transplantation
Figure S2 from HBV-Specific TCR–T Cell Therapy Combining mRNA Electroporation and Lentiviral Transduction: Treatment Regimen for Recurrent HBV-Related HCC after Liver Transplantation
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from HBV-Specific TCR–T Cell Therapy Combining mRNA Electroporation and Lentiviral Transduction: Treatment Regimen for Recurrent HBV-Related HCC after Liver Transplantation
Figure S2 from HBV-Specific TCR–T Cell Therapy Combining mRNA Electroporation and Lentiviral Transduction: Treatment Regimen for Recurrent HBV-Related HCC after Liver Transplantation
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from HBV-Specific TCR–T Cell Therapy Combining mRNA Electroporation and Lentiviral Transduction: Treatment Regimen for Recurrent HBV-Related HCC after Liver Transplantation
Figure S1 from HBV-Specific TCR–T Cell Therapy Combining mRNA Electroporation and Lentiviral Transduction: Treatment Regimen for Recurrent HBV-Related HCC after Liver Transplantation
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from HBV-Specific TCR–T Cell Therapy Combining mRNA Electroporation and Lentiviral Transduction: Treatment Regimen for Recurrent HBV-Related HCC after Liver Transplantation
Figure S1 from HBV-Specific TCR–T Cell Therapy Combining mRNA Electroporation and Lentiviral Transduction: Treatment Regimen for Recurrent HBV-Related HCC after Liver Transplantation
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from HBV-Specific TCR–T Cell Therapy Combining mRNA Electroporation and Lentiviral Transduction: Treatment Regimen for Recurrent HBV-Related HCC after Liver Transplantation
A–F, Changes in liver injury markers (ALT and AST) at different time points during HBV–TCR–T cell treatment. The shaded square area in the graph represents the reference range for each marker. The black dashed line indicates the time points of mRNA–HBV–TCR–T cell infusion, and the red dashed line indicates the time points of lenti-HBV–TCR–T cell infusion.
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from HBV-Specific TCR–T Cell Therapy Combining mRNA Electroporation and Lentiviral Transduction: Treatment Regimen for Recurrent HBV-Related HCC after Liver Transplantation
A–F, Changes in liver injury markers (ALT and AST) at different time points during HBV–TCR–T cell treatment. The shaded square area in the graph represents the reference range for each marker. The black dashed line indicates the time points of mRNA–HBV–TCR–T cell infusion, and the red dashed line indicates the time points of lenti-HBV–TCR–T cell infusion.
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Data from HBV-Specific TCR–T Cell Therapy Combining mRNA Electroporation and Lentiviral Transduction: Treatment Regimen for Recurrent HBV-Related HCC after Liver Transplantation
Purpose:This study aimed to preliminarily evaluate the safety, tolerability, and antitumor efficacy of hepatitis B virus (HBV)-specific T-cell receptor (TCR)–T cell therapy combining mRNA electroporation and lentiviral transduction in patients with recurrent HBV–hepatocellular carcinoma after liver transplantation.Patients and Methods:In this pilot study (NCT04677088), two types of autologous HBV-specific TCR-redirected T cells were assessed without prior lymphodepletion: (i) multiple infusions of mRNA-electroporated HBV–TCR–T cells (mRNA–HBV–TCR–T cells) and (ii) one to three infusions of lentiviral-transduced HBV–TCR–T cells (lenti-HBV–TCR–T cells). Treatment-related adverse events were assessed using the Common Terminology Criteria for Adverse Events, and antitumor efficacy was evaluated using CT imaging according to RECIST v1.1 criteria. Progression-free survival (PFS) was defined as the time from the start of study treatment until objective tumor progression or death.Results:Both mRNA-electroporated and lentiviral-transduced HBV-specific TCR–T cells demonstrated a favorable safety profile, with only grade 1 to 2 treatment-related adverse events observed. In the mRNA–HBV–TCR–T cells cohort, the median PFS was 2.32 months (range, 1.87–2.77 months). The combination therapy cohort (mRNA–HBV–TCR–T cells + lenti-HBV–TCR–T cells) showed a median PFS of 7.34 months (range, 4.47–7.60 months). CT imaging indicated effective tumor control in the combination therapy group.Conclusions:This study preliminarily suggests that the combination of mRNA–HBV–TCR–T cells and lenti-HBV–TCR–T cells could be a safe and potentially effective approach for treating patients following liver transplantation in the context of lifelong immunosuppression drug administration. Further studies are needed to refine treatment strategies and assess long-term safety and efficacy in this special patient population.
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from HBV-Specific TCR–T Cell Therapy Combining mRNA Electroporation and Lentiviral Transduction: Treatment Regimen for Recurrent HBV-Related HCC after Liver Transplantation
Purpose:This study aimed to preliminarily evaluate the safety, tolerability, and antitumor efficacy of hepatitis B virus (HBV)-specific T-cell receptor (TCR)–T cell therapy combining mRNA electroporation and lentiviral transduction in patients with recurrent HBV–hepatocellular carcinoma after liver transplantation.Patients and Methods:In this pilot study (NCT04677088), two types of autologous HBV-specific TCR-redirected T cells were assessed without prior lymphodepletion: (i) multiple infusions of mRNA-electroporated HBV–TCR–T cells (mRNA–HBV–TCR–T cells) and (ii) one to three infusions of lentiviral-transduced HBV–TCR–T cells (lenti-HBV–TCR–T cells). Treatment-related adverse events were assessed using the Common Terminology Criteria for Adverse Events, and antitumor efficacy was evaluated using CT imaging according to RECIST v1.1 criteria. Progression-free survival (PFS) was defined as the time from the start of study treatment until objective tumor progression or death.Results:Both mRNA-electroporated and lentiviral-transduced HBV-specific TCR–T cells demonstrated a favorable safety profile, with only grade 1 to 2 treatment-related adverse events observed. In the mRNA–HBV–TCR–T cells cohort, the median PFS was 2.32 months (range, 1.87–2.77 months). The combination therapy cohort (mRNA–HBV–TCR–T cells + lenti-HBV–TCR–T cells) showed a median PFS of 7.34 months (range, 4.47–7.60 months). CT imaging indicated effective tumor control in the combination therapy group.Conclusions:This study preliminarily suggests that the combination of mRNA–HBV–TCR–T cells and lenti-HBV–TCR–T cells could be a safe and potentially effective approach for treating patients following liver transplantation in the context of lifelong immunosuppression drug administration. Further studies are needed to refine treatment strategies and assess long-term safety and efficacy in this special patient population.
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Table 1 from HBV-Specific TCR–T Cell Therapy Combining mRNA Electroporation and Lentiviral Transduction: Treatment Regimen for Recurrent HBV-Related HCC after Liver Transplantation
Possible adverse effects associated with HBV–TCR–T cell treatment.
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from HBV-Specific TCR–T Cell Therapy Combining mRNA Electroporation and Lentiviral Transduction: Treatment Regimen for Recurrent HBV-Related HCC after Liver Transplantation
Possible adverse effects associated with HBV–TCR–T cell treatment.
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Table 2 from HBV-Specific TCR–T Cell Therapy Combining mRNA Electroporation and Lentiviral Transduction: Treatment Regimen for Recurrent HBV-Related HCC after Liver Transplantation
Summary of patient response to HBV–TCR–T cell treatment.
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from HBV-Specific TCR–T Cell Therapy Combining mRNA Electroporation and Lentiviral Transduction: Treatment Regimen for Recurrent HBV-Related HCC after Liver Transplantation
Summary of patient response to HBV–TCR–T cell treatment.